These independent CME/CE activities are supported by educational grants from Genentech BioOncology




Print PDF Clinician's Digest
An Ongoing Online CME/CE Curriculum
Caring for Oncology Patients: Tips and Tools for Managing Targeted Therapy
  1. Course List
Co-Chairs
faculty image
Theresa W. Gillespie, BA, BSN, MA, PhD, RN
  • Assistant Professor
  • Department of Surgery
  • Associate Director
  • Winship Cancer Institute
  • Emory University
  • Atlanta, Georgia
  • faculty image
    Hai T. Tran, PharmD
  • Assistant Professor Pharmacology
  • Divisions of Cancer Medicine and
  •   Pharmacy
  • The University of Texas
  • M.D. Anderson Cancer Center
  • Houston, Texas
  • This free and convenient online CME/CE program, co-chaired by Theresa W. Gillespie, BA, BSN, MA, PhD, RN, and Hai T. Tran, PharmD, promises to be a timely and continuously updated source of practical information that oncologists, nurses, and pharmacists can immediately use in treating, monitoring, and managing side effects in cancer patients receiving targeted therapy. Enroll today!
  • Assess the molecular basis of targeted therapy side effects to monitor for their onset and to successfully manage them to improve patients' QOL.
  • Differentiate between side effects of traditional oncology therapies vis-á-vis targeted therapies, to proactively monitor these side effects and ensure early intervention, to minimize side effects and improve adherence.
  • Evaluate current controversies and treatment regimens for preventing and managing side effects of targeted therapies to formulate practical strategic interventions (supportive and pharmacologic) that reflect the most up-to-date science and insights, and improve patient outcomes.
  • Target Audience

    Oncologists, oncology nurses, pharmacists, and other clinicians who specialize in caring for oncology patients on a day-to-day basis.

     

    Activity Goal

    The goal of these CME/CE activities is to examine current and emerging strategies for treating, monitoring, and managing side effects in cancer patients on targeted agents.